Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fulgent Genetics, Inc. (NASDAQ: FLGT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fulgent is a technology-based company with a laboratory services business and a therapeutic development business, and its SEC reports offer detailed information on both areas. Investors can review annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K to understand how the company presents its financial condition, results of operations, and material events.
Fulgent’s earnings-related 8-K filings reference press releases that discuss revenue, core revenue, GAAP and non-GAAP income or loss, gross profit and margin, and adjusted EBITDA. These filings also describe how the company defines and reconciles non-GAAP measures to the most directly comparable GAAP metrics, and how management uses these measures to evaluate performance. For those analyzing FLGT stock, these documents are a primary source for understanding trends in the laboratory services and therapeutic development segments, as well as the company’s cash position and stock repurchase activity.
In addition to financial results, Fulgent uses Form 8-K to report other significant developments, such as preliminary clinical data from its oncology programs. For example, the company has filed an 8-K to furnish a press release describing preliminary data from a phase 2 trial of FID-007 in combination with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma. Such filings provide context on the progress and risk profile of its therapeutic development pipeline.
On this page, users can track FLGT filings in near real time as they are made available through EDGAR. Stock Titan’s tools surface key forms such as 10-K for annual overviews, 10-Q for quarterly updates, and 8-K for material events, with AI-powered summaries that help explain complex sections and highlight important points. For those interested in governance, compensation, or potential insider activity, related SEC documents and forms can also be reviewed alongside the company’s broader disclosure record.
Fulgent Genetics (FLGT) insider sale by President & COO: On 08/27/2025, reporting person Xie Jian sold 1,199 shares of Fulgent common stock at a weighted-average price of $21.4847 to satisfy tax withholding from restricted stock units that vested from a Feb 26, 2024 RSU grant. After the sale, Mr. Xie beneficially owns 365,249 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust (where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest). The Form 4 reports the sale as a routine, nondiscretionary transaction to cover tax obligations rather than an open-market cash-raising sale.
Ming Hsieh, Chief Executive Officer, Director and 10% owner of Fulgent Genetics (FLGT), reported a small disposition of company stock on 08/26/2025. The Form 4 shows 2,944 shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units, at an effective price of $21.47 per share. After the transaction Mr. Hsieh directly beneficially owns 804,281 shares. He also reports indirect holdings of 7,895,115 shares held by a Dynasty Trust, 220,816 shares held by the Ming Hsieh Trust, and two 1,000-share Uniform Transfers to Minor Act accounts for which he is custodian. The form was signed by an attorney-in-fact on 08/28/2025.
Kim Paul, Chief Financial Officer and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a change in beneficial ownership. On 08/26/2025 the reporting person had 1,166 shares of common stock disposed of at a price of $21.47 per share, leaving 337,992 shares beneficially owned after the transaction. The filing explains those shares were withheld to satisfy tax-withholding obligations tied to restricted stock units that vested from a grant dated 02/26/2024 (originally reported 02/28/2024). The Form 4 is signed by Paul Kim on 08/28/2025.
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of 943 shares of the issuer's common stock on 08/27/2025 to satisfy tax withholding related to restricted stock units that vested from a grant made on 02/26/2024. The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66, with a reported weighted-average sale price of $21.4847. After the reported sale, the reporting person beneficially owned 958,148 shares directly. The Form 4 was signed by an attorney-in-fact, Paul Kim, on 08/28/2025. No derivative transactions or other amendments are disclosed in this filing.
Fulgent Genetics, Inc. filed a Form 144/A reporting a proposed sale of 1,135 shares of common stock through Morgan Stanley Smith Barney with an approximate aggregate market value of $23,030.08, to be sold on 06/02/2025 on NASDAQ. The filer acquired 32,000 restricted shares on 02/28/2022 through equity compensation from Fulgent Genetics, Inc. The filing also discloses two recent sales on 05/27/2025 of 690 and 1,183 shares producing gross proceeds of $14,196.92 and $24,271.47 respectively. The notice includes the standard signer representation that no undisclosed material adverse information is known.
Fulgent Genetics (FLGT) insider sale notice under Form 144/A: An individual affiliated with Fulgent Genetics reported a proposed sale of 696 shares of common stock through Morgan Stanley Smith Barney on 08/25/2025, valued at approximately $14,965.08. The shares were acquired on 02/23/2023 upon vesting of restricted stock awarded as equity compensation.
The filer also reported three prior sales in the past three months totaling 3,008 shares with gross proceeds of $61,398.47. Outstanding common shares are listed as 30,609,044, making these transactions immaterial to total share count. The filing is a routine Rule 144 compliance notice and includes the customary representation that no undisclosed material adverse information is known.
Form 144 filed for Fulgent Genetics, Inc. (FLGT) reporting a proposed sale of 1,199 shares of common stock through Morgan Stanley Smith Barney on 08/27/2025 on NASDAQ with an aggregate market value of $25,760.20. The filing shows the shares to be sold were acquired as restricted stock that vested on 02/26/2024 as equity compensation, with 25,350 shares originally issued to the holder on that date. The issuer has 30,609,044 shares outstanding per the notice. The filer disclosed multiple prior open-market sales by the same person in the past three months totaling 3,704 shares with gross proceeds reported on specific dates. The signer certifies no undisclosed material information and acknowledges Rule 144/10b5-1 representations.
Fulgent Genetics insider sale notice: This Form 144 reports that Hanlin Gao plans to sell 943 shares of Fulgent Genetics common stock through Morgan Stanley Smith Barney (New York) with an aggregate market value of $20,260.11 and an approximate sale date of 08/27/2025. The filing shows 30,609,044 shares outstanding for the issuer. The shares to be sold were acquired on 02/26/2024 as restricted stock that vested (21,146 shares acquired as equity compensation). The notice lists four prior sales by Hanlin Gao between 05/27/2025 and 08/25/2025, totaling 2,341 shares with gross proceeds reported for each transaction. The filer certifies no undisclosed material adverse information.
Xie Jian, President and COO of Fulgent Genetics (FLGT) reported a sale of 696 shares on 08/25/2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/23/2023. The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, with a reported weighted-average price of $21.5016. After the sale, the reporting person beneficially owns 366,448 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust, of which he serves on the investment committee and for which he disclaims beneficial interest except for any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Ming Hsieh, Fulgent Genetics (FLGT) director, CEO and 10% owner, reported a withholding of 2,115 common shares on 08/23/2025 at a price of $21.77 per share to satisfy tax withholding upon vesting of restricted stock units granted on 02/23/2023. After the withholding, Mr. Hsieh directly holds 807,225 shares and retains substantial indirect holdings: 7,895,115 shares held by a Dynasty Trust, 220,816 shares held by the Ming Hsieh Trust, and two 1,000-share UTMA accounts for which he is custodian. The Form 4 was signed by an attorney-in-fact on 08/26/2025. The filing clarifies the trust relationships and voting/dispositive powers for the indirect holdings.